Ghrelin Levels in Pancreatic Cancer Patients

NCT00225745 | Completed DMC

• 1 other identifier: DMS 0405
• Study Type: observational
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

The primary outcome measure for this study is plasma ghrelin level.

Conditions

Pancreatic Cancer

Keywords

Ghrelin

Outcome Measures

Primary Outcomes (1)

• To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls

  prior to treatment

Secondary Outcomes (2)

• To investigate the role of ghrelin in pathophysiology of cancer cachexia

  prior to treatment

• To generate hypotheses for future studies and treatment based on the findings

  prior to treatment

Study Arms (2)

1

Pancreatic cancer patients

Procedure: Blood draw

2

Healthy controls

Procedure: Blood draw

Interventions

Blood draw PROCEDURE

One blood draw prior to first treatment

1; 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Pancreatic cancer patients who have not received treatment. Healthy age-matched controls.

You may qualify if:

• Histological or cytological proof of pancreatic adenocarcinoma
• The control are will include healthy age-matched patients without cancer
• The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss
• Patients must have recovered from any major infections and/or surgical procedures

You may not qualify if:

• Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state
• Patients on appetite stimulant and those receiving total parenteral nutrition
• Patients who have undergone gastrectomy or those who have gastric ulcers
• Patients receiving active chemotherapy
• No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.

Sponsors & Collaborators

• Dartmouth-Hitchcock Medical Center: lead

Study Sites (1)

Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center

Lebanon, New Hampshire, 03756, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Whole Blood

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• J Marc Pipas, MD

  Dartmouth-Hitchcock Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2005
• First Posted: September 26, 2005
• Study Start: April 1, 2004
• Primary Completion: October 1, 2013
• Study Completion: September 1, 2015
• Last Updated: October 14, 2015

Record last verified: 2015-08

Locations

US (1)